Our MBC Life

SS24 E02 Report Back From ASCO 2024: What’s the Latest in HR+ MBC?

July 31, 2024 SHARE Cancer Support
SS24 E02 Report Back From ASCO 2024: What’s the Latest in HR+ MBC?
Our MBC Life
More Info
Our MBC Life
SS24 E02 Report Back From ASCO 2024: What’s the Latest in HR+ MBC?
Jul 31, 2024
SHARE Cancer Support

Today, we’re bringing you a very special episode created in partnership with SHARE Cancer Support. This is an audio version of our Webinar Report Back from ASCO 2024: Latest Updates on Metastatic Breast Cancer (MBC). 

We're excited to present this report from the 2024 ASCO Annual Meeting, highlighting the latest advancements and research in hormone receptor positive (HR+)  metastatic breast cancer. 

In today's episode, you will hear from Dr. Kevin Kalinsky, a medical oncologist and investigator from Emory. We will dive deep into the findings from the DESTINY-Breast06 trial and the postMONARCH trial. We'll explore the implications of these studies, how they could impact treatment strategies, and what this means for us. 

Show Notes

Today, we’re bringing you a very special episode created in partnership with SHARE Cancer Support. This is an audio version of our Webinar Report Back from ASCO 2024: Latest Updates on Metastatic Breast Cancer (MBC). 

We're excited to present this report from the 2024 ASCO Annual Meeting, highlighting the latest advancements and research in hormone receptor positive (HR+)  metastatic breast cancer. 

In today's episode, you will hear from Dr. Kevin Kalinsky, a medical oncologist and investigator from Emory. We will dive deep into the findings from the DESTINY-Breast06 trial and the postMONARCH trial. We'll explore the implications of these studies, how they could impact treatment strategies, and what this means for us.